ERS 2026: AstraZeneca’s IL-33 inhibitor tozorakimab reduces mucus plug burden in COPD
At ERS 2026, AstraZeneca presented new Phase III data on the impact of tozorakimab versus placebo on mucus plugs in patients with COPD.
Read the full article on the original site.
Read Full Article